1-[(2,4-dichlorophenyl)methyl]-4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]pyrazolo[5,4-d]pyrimidine
C22H22Cl2N8 — CID 658536
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[(2,4-dichlorophenyl)methyl]-4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]pyrazolo[5,4-d]pyrimidine
1-[(2,4-dichlorophenyl)methyl]-4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]pyrazolo[5,4-d]pyrimidine (PubChem CID 658536) has the molecular formula C22H22Cl2N8 and a molecular weight of 469.38 g/mol. Its IUPAC name is 1-[(2,4-dichlorophenyl)methyl]-4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]pyrazolo[5,4-d]pyrimidine.
Molecular Properties
| Compound Name | 1-[(2,4-dichlorophenyl)methyl]-4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]pyrazolo[5,4-d]pyrimidine |
|---|---|
| PubChem CID | 658536 |
| Molecular Formula | C22H22Cl2N8 |
| Molecular Weight | 469.38 g/mol |
| Exact Mass | 468.13 |
| IUPAC Name | 1-[(2,4-dichlorophenyl)methyl]-4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]pyrazolo[5,4-d]pyrimidine |
| SMILES | Cc1cc(C)nc(N2CCN(c3ncnc4c3cnn4Cc3ccc(Cl)cc3Cl)CC2)n1 |
| InChI | InChI=1S/C22H22Cl2N8/c1-14-9-15(2)29-22(28-14)31-7-5-30(6-8-31)20-18-11-27-32(21(18)26-13-25-20)12-16-3-4-17(23)10-19(16)24/h3-4,9-11,13H,5-8,12H2,1-2H3 |
| InChIKey | LDDHAEXRRUSODZ-UHFFFAOYSA-N |
| XLogP | 3.91 |
| TPSA | 75.86 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 469.38 |
| LogP ≤ 5 | 3.91 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 658536 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.